Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential treatment strategy for metastatic colorectal cancer with chemotherapy with or without bevacizumab followed by second-line randomized studies with bevacizumab and/or cetuximab
2007-004539-44Phase 3Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab and cetuximab in colorectal cancer (CRC) and rectosigmoid cancer (5 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Overall survival and Total progression-free survival. Started Nov 2007; status: completed.
02
Drugs
bevacizumabcetuximab
03
Conditions
colorectal cancer (CRC)rectosigmoid cancer
Beyond the preview
Go deeper on 2007-004539-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004539-44.